Pharmacological aspects of Vipera xantina palestinae venom - Wikidata - awgldk - TriplyDB

Pharmacological aspects of Vipera xantina palestinae venom

Pharmacological aspects of Vipera xantina palestinae venom

http://www.wikidata.org/entity/Q27005573

about

Evaluation of antivenom therapy for Vipera palaestinae bites in children: experience of two large, tertiary care pediatric hospitals.Anti-angiogenic activities of two recombinant disintegrins derived from the Mohave and Prairie rattlesnakes.Venom gland transcriptome analyses of two freshwater stingrays (Myliobatiformes: Potamotrygonidae) from Brazil.The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.Vixapatin (VP12), a c-type lectin-protein from Vipera xantina palestinae venom: characterization as a novel anti-angiogenic compound Distribution of RPTLN Genes Across Reptilia: Hypothesized Role for RPTLN in the Evolution of SVMPs.Antiadhesive and cytotoxic effect of Iranian Vipera lebetina snake venom on lung epithelial cancer cells.

P2860

Q33168160-94BA715C-6DB0-4777-9C58-DEEECE1BB42A Q34730272-C58B7356-A088-4167-8959-30038D77897A Q36621255-17841D04-EC02-4D7D-B5A4-1E4E766E53C0 Q39181842-44D85B0C-7C4C-457B-AE66-47C40D86E53C Q39242748-D1A20BE3-2682-4EC9-8D87-AF0C6522895F Q43719947-94572BAD-8A0B-46DE-9ABD-DD3B997B8B0F Q55285325-6AF9D1B3-DB8A-43E9-9F1B-87646E354709

P2860

Pharmacological aspects of Vipera xantina palestinae venom

http://www.wikidata.org/entity/Q27005573

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacological aspects of Vipera xantina palestinae venom

@ast

Pharmacological aspects of Vipera xantina palestinae venom

@en

Pharmacological aspects of Vipera xantina palestinae venom

@nl

type

label

Pharmacological aspects of Vipera xantina palestinae venom

@ast

Pharmacological aspects of Vipera xantina palestinae venom

@en

Pharmacological aspects of Vipera xantina palestinae venom

@nl

prefLabel

Pharmacological aspects of Vipera xantina palestinae venom

@ast

Pharmacological aspects of Vipera xantina palestinae venom

@en

Pharmacological aspects of Vipera xantina palestinae venom

@nl

P1433

Q27005573-0E676267-A28E-48A5-BD48-63148E35A365

P1476

Q27005573-1CF8FA09-72F5-488C-BA6B-FC5AFDE9714D

P2093

Q27005573-402B004E-47B8-47E1-B597-45865F5392AB

Q27005573-4379256C-1367-4ED8-9927-BE21F542D95E

Q27005573-5789A588-A7BB-4F9C-8C4E-1B6A6EC02CF7

Q27005573-89D7A77F-2474-44E1-939B-01EB2312AA74

Q27005573-CFA18FE5-597D-4782-B974-2FA54AF8D487

Q27005573-FF342887-4046-437D-A718-5DF10D71C800

P2860

Q27005573-1304C4FC-AE8D-4BE0-B7A0-CDEA0BF3B779

Q27005573-16A8831D-7F4A-41AC-B588-73652F760322

Q27005573-16FE0BBF-C797-4A14-9E12-338749111419

Q27005573-2490950F-E652-4AE3-BC2B-564357557851

Q27005573-2AC9BA23-40F3-43AA-A330-F9F3451F23F1

Q27005573-2D1DF8DE-694A-4CEA-BC4C-40D7AD22B3FE

Q27005573-2EEE945A-9367-4B4C-9612-8CF0E7D5CCA4

Q27005573-36A2F69F-1C9B-45A8-8162-7988B35564E9

Q27005573-37469254-F765-4C56-901A-4F0169199808

Q27005573-384D9127-6637-43E4-8261-274C6333A468

P304

Q27005573-B165767C-FE1F-4D11-ADA1-EE9AD78C3CCF

P31

Q27005573-8C2E183E-23FF-4281-A9F8-617E10A58CB8

P356

Q27005573-1A333E31-F03F-47BD-AB48-1AE91608024E

P407

Q27005573-44A9AF6C-637F-4444-814B-8A25112C0AE1

P433

Q27005573-B9CDA40A-F3A0-4CFB-A401-7E6CBD806A0F

P478

Q27005573-A19FA5B9-75A3-466F-820F-7C62AB60A476

P50

Q27005573-AF827C2B-AD04-48A3-848B-BF48B8D90EF5

P577

Q27005573-CC0A1017-E490-4B78-A411-D50F1930405B

P5875

Q27005573-FD2A3221-8ED6-44CA-8C0C-29693DF13524

P698

Q27005573-3251AC59-131F-4282-9786-4C5A01B6798B

P921

Q27005573-791E42B4-84CE-4075-B1D1-950EC0FB4008

Q27005573-9E099385-2F11-493D-9E9E-30534300E801

P932

Q27005573-689D63B2-A4B2-4294-8003-F3BA8368A007

P356

P1433

P1476

Pharmacological aspects of Vipera xantina palestinae venom

@en

P2093

Cezary Marcinkiewicz

http://www.w3.org/2001/XMLSchema#string

Franziska T Arlinghaus

http://www.w3.org/2001/XMLSchema#string

Hadar Arien-Zakay

http://www.w3.org/2001/XMLSchema#string

Jeoshua Katzhendler

http://www.w3.org/2001/XMLSchema#string

Johannes A Eble

http://www.w3.org/2001/XMLSchema#string

Philip Lazarovici

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4

The alpha2beta1 integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule

Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]

Integrin signaling

Biochemical signals and biological responses elicited by the focal adhesion kinase

P304

1420-1432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/TOXINS3111420

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51884936

http://www.w3.org/2001/XMLSchema#string

P698

22174978

http://www.w3.org/2001/XMLSchema#string

P921

P932

3237004

http://www.w3.org/2001/XMLSchema#string